Researchers in Taiwan find no difference in fungal disease among patients treated with two different types of GVHD ...

Orca Bio’s T-cell immunotherapy candidate for blood cancers has more than doubled the number of patients surviving free of ...

Approximately two-thirds of patients responded to teduglutide, which is sold under the brand name Gattex as a treatment for ...

Orca-T, an investigational allogeneic T-cell immunotherapy, improved cGVHD-free survival compared with allo-HSCT in patients with acute leukemia or MDS in the phase 3 Precision-T trial (NCT05316701).

If preclinical findings were translated into the clinic, they could shorten the CAR-T generation lead time from two weeks to one day.

USC researchers have developed an innovative type of cancer-fighting immune cell, the EchoBack CAR T-cell, that uses focused ...

GVHD is one of the leading causes of death in patients receiving donor stem cell transplants ... but in around 15% of cases can’t resolve the acute inflammatory response. In those cases ...

Steroid-refractory acute GvHD is a serious and life-threatening condition that can occur as a complication of donor haematopoietic stem cell transplantation ... In patients who don't respond ...

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers ...

High Treatment Costs High treatment costs represent one of the most significant barriers in the GVHD treatment market, as patients face substantial financial challenges. The expenses associated with ...